Skip to main content

Lung Cancer


Higher out-of-pocket costs for TKIs are associated with decreased therapy adherence among patients with EGFR- and ALK-positive NSCLC.
Study findings show TKI therapy, immunotherapy, and chemotherapy are relatively small drivers of unplanned acute…
A recent analysis finds adherence to lung cancer screening is much lower than reported in large randomized clinical…
FDA Approval
The FDA granted approval to osimertinib as adjuvant therapy after tumor resection for patients with NSCLC and EGFR…
Study results show timely specialty palliative care for patients with metastatic NSCLC is associated with lower health…
Back to Top